Q3 2025 Management View CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "treatment with inhaled ...
Subtle changes in your fingers or nails may warn of lung cancer. Experts explain early signs like clubbing, swelling, and ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Stress CMR significantly enhances diagnostic accuracy for chest pain without obstructive coronary artery disease, identifying ...
Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...
CT scans are becoming a more commonly used tool to effectively determine a patient's future risk of heart disease and heart ...
Heather Quintana was feeling under the weather for weeks. She was sent to the doctor a few times, believing she had pneumonia ...
Lung cancer is the leading cause of cancer deaths in the U.S., killing more people than the next three causes of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback